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1. INTRODUCTION & PURPOSE 
This document details the statistical analysis proposed and the presentation that will 
be followed, as closely as possible, when analysing and reporting the median 15-
year results from the Prostate Testing for Cancer and Treatment (ProtecT) 
Study. As far as possible this plan will follow the approaches in the main ProtecT 
statistical analysis plan written for the primary analysis of median 10-year follow-up, 
which is available at: https://njl-admin.nihr.ac.uk/document/download/2021093 
 
The purpose of the plan is to:  
1. Make explicit the details of the planned analysis, as agreed with the Trial 
Steering Committee. 
2. Ensure that the analysis is appropriate for the aims of the trial, reflects good 
statistical practice, and that interpretation of a priori and post-hoc analyses is 
appropriate. 
3. Explain in detail how the data will be handled and analysed to enable others 
to perform the actual analysis in the event of sickness or other absence, or to 
replicate the analyses 
 
Additional exploratory or auxiliary analyses of data not specified in the protocol are 
permitted but fall outside the scope of this analysis plan (although such analyses 
would be expected to follow Good Statistical Practice). 
The analysis strategy will be made available if required by journal editors or referees 
when the main papers are submitted for publication.  Additional analyses suggested 
by reviewers or editors will, if considered appropriate, be performed in accordance 
with the Analysis Plan, but if reported the source of such a post-hoc analysis will be 
declared. 
Amendments to the statistical analysis plan will be described and justified in the final 
report of the trial. 
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2. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
IMPORTANT: This synopsis is purely to provide background information for those 
reading the statistical analysis plan. It does not replace the study protocol; the 
current version of which must be consulted for all other purposes. 
 
2.1. Trial objectives and aims 
The ProtecT trial was designed in the late 1990s and early 2000s to compare the 
major conventional treatments for patients with clinically localised prostate cancer 
detected through population-based PSA testing. The three treatments were radical 
prostatectomy, external beam three-dimensional (3D) conformal radiotherapy, and 
active monitoring. 
 
2.1.1. Primary objective 
In men with localised prostate cancer detected through population-based PSA 
testing, to compare definite or probable prostate cancer specific mortality (including 
definite or probable intervention related mortality) at a median of 10 years following 
random allocation to radical prostatectomy, external beam three dimensional (3D) 
conformal radiotherapy, and active monitoring. 
 
2.1.2. Secondary objectives 
To make the same comparison on a number of secondary outcome measures, 
including overall survival, clinical disease progression, treatment complications, 
lower urinary tract symptoms, quality of life, and sexual function. To estimate the 
resource use and costs of case-finding, treatment and follow-up, and to compare 
costs and outcomes of treatment in terms of survival and health related quality of life. 
 
2.2. Trial design and configuration 
A three parallel groups randomised controlled trial. 
 
2.3. Trial centres 
Recruitment to the trial took place at general practices in and around nine study 
centres across the UK: Newcastle, Sheffield, Bristol, Cardiff, Edinburgh, Birmingham, 
Leicester, Cambridge, and Leeds. 
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2.4. Eligibility criteria 
2.4.1. Inclusion criteria  
• Men 
• Age 50-69 years on the date of preparation at the general practice of the list 
of potential participants 
• Able to give written informed consent to participate 
• Fit for any of the three treatments and with a life expectancy of at least 10 
years 
• Registration with the participating general practice on the date of the PCC 
• For randomisation: clinically localized prostate cancer (confirmed by isotope 
bone scan in men with PSA of 10ng/L or more) diagnosed by 10-core biopsy 
following a PSA level of 3ng/L or more. 
 
2.4.2. Exclusion criteria 
• Concomitant or past malignancies (other than a small treated skin cancer) 
• Prior treatment for prostate malignancy 
• Serious cardiac or respiratory problems in the previous 12 months of the PCC, 
e.g. stroke, MI, heart failure, COPD 
• Kidney dialyses or transplantation 
• Bilateral hip replacement 
• Previous entry to the ProtecT study at a prior general practice 
• PSA 20ng/L or more at diagnosis 
 
2.5. Description of interventions 
The Active Monitoring Protocol aimed to avoid immediate radical treatment whilst 
assessing the disease over time, with a review and the opportunity for radical 
treatment if there was evidence of disease progression. PSA levels were measured 
and reviewed every three months in the first year and twice yearly thereafter. 
Changes in PSA levels were assessed, and a rise of at least 50% over the previous 
12 months triggered repeat testing within six to nine weeks. If the PSA levels were 
persistently raised, or th e patient had other concerns, a review appointment was 
made to consider treatment options. 
The Radiotherapy Protocol began with neoadjuvant androgen suppression, given 
for three to six months before and concomitantly with 3D-conformal radiation therapy 
delivered at 74 Gy in 37 fractions. 
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Surgery was a radical retropubic prostatectomy procedure. The surgical approach 
was left to the discretion of the surgeon, and was most commonly open, but 
laparoscopic, or robot-assisted approaches were permitted from 2003. 
 
2.6. Randomisation procedures 
Randomisation was stratified by centre with stochastic minimization by age at 
invitation, Gleason score (primary and secondary grades), and mean of baseline and 
first biopsy PSA results. Men who declined randomisation were offered identical 
follow-up and formed an observational patient preference cohort. 
 
2.7. Blinding 
The process used to assess cause of death was adapted from the PLCO algorithm 
and ERSPC process. The medical records of deceased participants were 
summarised by trained researchers, anonymised and reviewed by an independent 
endpoint committee. Table 1 presents the classification of deaths by study arm. 
 
2.8. Trial committees 
For the current period of follow-up, ProtecT has a Trial Steering Committee, chaired 
by Professor Deborah Ashby (Imperial College).  
 
2.9. Outcome measures 
2.9.1. Primary outcome 
The primary outcome is definite or probable prostate cancer mortality, including 
intervention-related deaths, at a median 10 years’ follow-up. 
We will repeat the analysis of definite or probable prostate cancer mortality, including 
intervention-related deaths, at 10 years (with all participating men having more than 
10 years’ follow-up) and at the median 15 years’ follow-up.  
As previously the plan is for the primary outcome measure to be determined by the 
independent cause of death committee. If this proves not possible, we will rely on 
certified underlying cause of death where necessary. 
 
 
2.9.2. Secondary outcomes 
Secondary clinical and patient-reported outcomes to be presented in the 15-year 
results papers are: 
• overall mortality 
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• metastatic disease 
• clinical disease progression 
• initiation of long-term hormone therapy 
• patient reported outcomes (PROMs) 
Metastatic disease is defined as positive imaging showing bony, visceral and/or 
lymph node metastases, or PSA above 100; or bone marrow infiltration with 
associated systemic symptoms.  
Clinical disease progression will be measured as person-years free of the 
consequences of disease progression. Signs of disease progression will include 
evidence of metastatic disease; the initiation of long-term hormone therapy; 
diagnosis of clinical T3 or T4 disease; or ureteric obstruction, rectal fistula, or the 
need for a permanent catheter when these are not considered to be a complication 
of treatment. There will be a review of cases where disease progression or 
metastatic disease are uncertain. 
As the ascertainment of clinical disease progression may differ between the three 
study arms, we will also present the initiation of long-term hormone therapy, to 
indicate those men whose disease is no longer curable. 
The reporting of metastatic disease, clinical disease progression, and initiation of 
long-term hormone therapy is conditional on securing the data. 
The patient-reported outcomes which have been measured are listed in the 
Appendix. These measures are derived from validated questionnaires and have 
been completed at recruitment, at first biopsy, six months after randomisation, and 
yearly thereafter. These measures will be reported in a separate companion paper, 
to be submitted for publication at the same time as the primary outcomes paper. 
 
 
2.10. Interim analysis 
There have been no analyses of the outcome data that have accumulated since 
publication of the findings at median ten-years follow-up. 
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3. GENERAL ANALYSIS CONSIDERATIONS 
3.1. Analysis populations 
The primary analysis data set is all men randomly allocated to one of the three 
management options being compared in the ProtecT trial. 
 
3.2. Procedures for missing data 
Where a man has omitted responding to a small number of items on a patient 
reported outcome measure, these will be imputed as per the guidance for that 
measure.  
Where the patient has not responded to any or most of the items on a measure, the 
main analysis of patient-reported outcomes will NOT be based on data with those 
missing scale scores imputed. However, the amount of missing data, by allocation 
arm, will be presented. All men providing at least one post-randomisation patient-
reported measure will be included in the relevant analysis. 
 
3.3 Definitions of treatment received 
Men were considered to have received each of the treatments according to the 
following definitions; men who did not fulfil these were excluded. 
1. Active Monitoring (AM) if there were ≥ two PSA tests and no radical treatment in 
the 12 months following diagnosis. 
2. Surgery (RP) if RP carried out within 12 months following diagnosis.  
3. Radiotherapy (RT) if treatment protocol was started within 12 and completed 
within 15 months. 
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4. DESCRIPTION OF PARTICIPANT CHARACTERISTICS 
4.1. Disposition 
Details of the recruitment of the ProtecT randomised trial cohort, up to the point of 
randomisation, were presented in the Baseline Paper (Lane et al, 2014). Details of 
how many men were excluded and for what reasons are presented. The subsequent 
flow of patients through the trial will be summarised in a CONSORT diagram that will 
include the numbers randomised to the three treatment groups, losses to follow-up 
and the numbers analysed. This extends the diagram in Hamdy et al (2016) to make 
clear losses to follow-up since the median ten-year follow-up (Figure 1). 
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5. ANALYSIS OF EFFECTIVENESS 
5.1. Summary of outcomes to report at median 15 years follow-up 
The following summaries of the outcome events will be presented for each treatment 
allocation group:  
• Number of deaths due to prostate cancer. 
• Prostate cancer mortality at 15 years, with 95% confidence interval.  
• Prostate cancer mortality per 1,000 person years of follow-up, with 95% 
confidence interval.  
• Kaplan-Meier survival of death from prostate cancer as a function over time. 
The following summaries will be presented for the clinical secondary outcome 
events: 
• Number of events. 
• Events per 1000 person years of follow-up, with 95% confidence interval. 
• Kaplan-Meier overall survival and survival free of disease progression as 
functions over time 
In addition, if the data can be obtained, the Kaplan-Meier cumulative incidence of the 
uptake of radical treatment will be presented for the three treatment groups as a 
function over time. 
 
5.2. Prostate cancer mortality at median 15 years follow-up 
This analysis will be conducted on an intention-to-treat basis comparing allocated 
groups. Deaths occurring until a median of 15-year follow-up has accumulated 
(23:59 on Monday 23rd November 2020) will be included in the locked database. We 
will allow up to 30th June 2021 to be notified of deaths (we may revise this deadline 
for notification if the COVID-19 outbreak causes delays). 
Prostate cancer (definite, probable, or intervention-related) mortality will be 
compared between the three treatment groups using Cox’s proportional hazards 
regression adjusted for study centre (all nine centres distinguished using dummy 
variables), age at baseline (continuous measure in years), Gleason score (2-6, 7, 8-
10), and PSA at baseline (continuous measure in ng/ml, log-transformed to 
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β1j is the log hazard ratio comparing two of the treatment arms, with two of the three 
pairwise comparisons being available from a single iteration of the analysis (i.e. j=1,2 
the estimated comparisons depending on the choice of comparator treatment). x1i is 
the treatment allocation (0,1,2) for participant i. β2k (k=1 to 8) captures differences in 
the hazard of the primary outcome event between study centres, x2i being the study 
centre for participant i. β3 is the linear effect of age, with x3i being the age in years for 
participant i. β4m (m=1,2) accommodates the effect of Gleason score category with 
x4i being the Gleason score category for participant i. Finally β5 is the linear effect of 
log-transformed PSA level, x5i being the PSA level at diagnosis for participant i.  
Plots and tests based upon Schoenfeld residuals will be investigated to determine 
whether the proportional hazards assumption is reasonable; if not the model will be 
elaborated to allow for a changing magnitude of treatment effect with time. 
The hazard ratio and 95% confidence interval for the treatment effect estimated in 
each pairwise comparison of allocated treatments will be presented, but pairwise 
significance tests will only be conducted if a test of an equal 15-year disease specific 
mortality risk across all three arms yields a p-value of less than 0.05 (Table 3). This 
conditional approach keeps the overall false positive rate at 5% and has been found 
to maintain power in simulation studies (Bauer 1991). 
The competing risk of all-cause death is not anticipated to influence the estimation of 
the treatment effect on the risk of prostate cancer mortality. Age is the only strongly 
influential risk factor shared by all-cause and prostate cancer mortality, and age is 
included as a covariate in all models. 
 
5.3. Other analyses at median 15-years follow-up 
The approach to the primary analysis will be adapted to the analysis of secondary 
outcome events, i.e. definite, probable or possible prostate cancer mortality; all-
cause mortality; and metastatic cancer. 
For patient reported outcomes (see Section 2.9.2) summary statistics by allocated 
group will be presented graphically for the baseline, 6-month, 12-month and 
subsequent assessment points up to 12 years (we will accept questionnaires 
returned by September 30th 2021, by which time all men will have this duration of 
follow-up). This approach will also be taken for those questionnaires dropped from 
the battery in November 2018, with the consequent loss of responses for later 
assessment points being made clear. All graphical presentations will present the full 
12 years follow-up but will focus on the novel data for the period from 73 to 132 
months.  
Analyses will employ multi-level models for repeated measures to estimate average 
treatment effects. These analyses will be adjusted for the stratification (centre) and 
minimisation (baseline age, Gleason score, PSA level) variables as described in the 
previous section. Consistent with the focus of the current analysis, the null 
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hypothesis of no difference in the population means of an outcome measure 
between allocated treatment groups, for the period from 73 to 144 months, will be 
tested. 
 
5.4. Subgroup analyses 
Following peer-reviewed criteria for the credibility of subgroup analyses (Sun et al, 
2010), we have pre-specified a small number of subgroup analyses investigating 
whether treatment effectiveness in reducing prostate cancer specific mortality is 
modified by the following factors measured at diagnosis: 
• Age (above versus below 65 years) 
• Grade Group (Group 1 versus Group 2; Group 2 versus Group 3+) 
• PSA (PSA < 10ng/ml versus 10 and above) 
• Clinical stage (T1 versus T2)  
• Aggregate tumour length in biopsy cores (<4mm versus 4mm+) 
• Maximum tumour length in a single biopsy core (<2mm versus 2mm+) 
• D’Amico low risk versus moderate / high risk. 
• CAPRA low risk (score 0-1) versus moderate / high risk (>1) 
Age, clinical stage, grade group, tumour burden and PSA are commonly used factors 
in the prediction of risk of disease progression. We anticipate that men at the lowest 
risk of disease progression have least to gain from radical treatment in comparison 
to their outcome with active monitoring. Wilt et al (2020) obtained results consistent 
with this hypothesis.  
The D’Amico risk categories (D’Amico, 1998) are low (Gleason score is 6 or less, 
and PSA is 10ng/ml or less, and clinical stage is T1c/T2a); high (Gleason score is 8 
or more, or PSA more than 20ng/ml, or stage is T2c); and intermediate (Gleason 
score is 7, or PSA is higher than 10ng/ml but no more than 20ng/ml, or stage is T2b). 
To facilitate comparison of our results to those of Wilt et al (2020) we have adopted 
the CAPRA score of disease risk (Cooperberg et al, 2006) and will repeat this set of 
subgroup analyses with all-cause mortality as the outcome measure.  
The statistical models used in the primary analysis will be extended to incorporate 
interaction terms, to test null hypotheses of no variation in treatment effect across 
subgroups. For sub-group analyses based on age, PSA, and tumour length 
measures, the interaction test will be based on the continuous measure, and 
departures from the assumption of a linear relationship will be investigated (and 
accommodated if necessary) by introducing polynomial terms. Significance testing 
will be conducted with the principles of the primary analysis being followed as closely 
as possible. 
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We will also investigate whether the relative impact of intervention on key PROMs 
(pad use, nocturia, erectile dysfunction , and bloody stools) is modified by age and 
the risk of disease progression at baseline, as incorporated for the clinical measures. 
 
5.5. Sensitivity analyses 
The analysis of prostate cancer mortality will be repeated, but with the outcome 
defined as death definitely, probably and possibly due to prostate cancer. 
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6.  15-YEAR PUBLICATION PLAN 
6.1. Planned papers and timelines 
The intention is to present the clinical and patient-reported outcomes in a pair of 
papers, to be submitted to a high impact medical journal by late 2021. With a census 
date of 23rd November 2020 for clinical outcomes contributing to this analysis, this 
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7. FINAL REPORT TABLES AND FIGURES 
 
Figure 1. CONSORT flowchart, illustrating the flow of participants through each of 
the three arms of the trial, from the point of randomisation.  
 
 1643 participants were randomly assigned 
553 allocated 
to surgery 
### began allocated 
protocol by 12 mths 
 
545 allocated to active 
monitoring protocol 
### began allocated 
protocol by 12 mths 
 
545 allocated to 
radiotherapy protocol 
### began allocated 
protocol by 12 mths 
 
545 included in 
10-year analysis 
553 included in 
10-year analysis 
545 included in 
10-year analysis 
6 Lost to FU 3 Lost to FU 5 Lost to FU 
### included in 
15-year analysis 
# Lost to FU 
### included in 
15-year analysis 
# Lost to FU 
### included in 
15-year analysis 
# Lost to FU 
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Figure 2. Kaplan-Meier estimates of the cumulative probability of undergoing radical 
interventions during the follow-up period, according to treatment group.  
Radical intervention was defined as a radical prostatectomy, per-protocol radiotherapy, non-
protocol radiotherapy (including brachytherapy), or high-intensity focussed ultrasound 
therapy. 
 
Figure 3. Kaplan-Meier estimates of prostate cancer-specific survival and freedom 
from disease progression, according to treatment group: active monitoring (solid 
line), surgery (long dash line) and radiotherapy (short dash line) treatment groups 
Panel A shows the rate of prostate cancer-specific survival. Prostate cancer-specific deaths 
were those that were definitely or probably due to prostate cancer as determined by an 
independent cause-of-death evaluation committee whose members were unaware of 
treatment assignments. 
Panel B shows the rate of overall survival.  
Panel C shows the rate of freedom from disease progression. Clinical progression of 
prostate cancer included metastases and death due to prostate cancer or its treatment. 
17 | P a g e  
ProtecT 15 years SAP version 1.0 19/11/2020 
Table 1. Prostate cancer mortality, Clinical progression, metastatic disease and all-cause mortality, by randomised group 








Total person years in follow-up     
Number of deaths due to prostate cancer2     
% prostate cancer mortality at median 10 years (95% CI)     
% prostate cancer mortality at median 15 years (95% CI)     
Prostate cancer deaths1 per 1000 person years (95% CI)     
     
Number of deaths due to any cause         
All-cause deaths per 1000 person years (95% CI)        
     
Person years of follow-up free of hormone treatment     
Number of men treated with hormones for advanced disease     
Starting hormone treatment per 1000 person years (95% CI)     
     
Person years of follow-up free of clinical progression3     
Number of men with clinical progression      
Clinical progression per 1000 person years (95% CI)     
        
Person years of follow-up free of metastatic disease        
Number of men with metastatic disease        
Metastatic disease per 1000 person years (95% CI)        
1 Likelihood ratio test of the null hypothesis “no difference in prostate cancer mortality between the three treatment arms”, adjusted for study centre, age, 
mean PSA at prostate check clinic and biopsy, and Gleason score at baseline. 2Death probably or definitely due to prostate cancer or its treatment as judged 
by an independent committee. 3Disease progression includes evidence of metastatic disease; the initiation of hormone therapy; diagnosis of clinical T3 or T4 
disease; or ureteric obstruction, rectal fistula, or the need for a permanent catheter when these are not considered to be a complication of treatment. 
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Table 2. Prostate cancer deaths by randomised group and subgroup 
 Rate prostate cancer mortality1 per 1000 person years 
(number of deaths) 
 








Age at randomization     
  < 65 years     
  65 years+     
     
Grade group at diagnosis     
  Group 1     
  Group 2     
  Group 3+     
     
Aggregate tumour length in 
biopsy cores 
    
  <4mm     
  4mm+     
     
Maximum tumour length in any 
single biopsy core 
    
  <2mm     
  2mm+     
     
PSA level at diagnosis     
  < 10 ng/ml     
  10 ng/ml+     
     
Clinical stage at diagnosis     
  T1c      
  T2     
     
CAPRA risk score     
  Low risk (score 0-1)     
  Medium / high risk (score >1)     
     
D’Amico risk group     
  Low     
  Intermediate / high     
1Death probably or definitely due to prostate cancer or its treatment as judged by an independent 
committee.2Likelihood ratio test of the null hypothesis “equal relative treatment effects across the 
subgroups”, adjusted for study centre, age, mean PSA at prostate check clinic and biopsy, and 
Gleason score at baseline. 
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8. APPENDIX 
The following standard assessment tools have been completed by men participating 
in the ProtecT study: 
 
• Expanded Prostate Index Composite 
• International Consultation on Incontinence Questionnaire (ICIQ) 
• International Continence Society urinary function (ICSmaleSF) 
• EORTC QLQ-C30 cancer-specific impacts 
• Hospital Anxiety and Depression Scale (Until November 2018) 
• Short Form 12 (SF-12) mental and physical subscales (Until November 2018) 
• EuroQoL-5D (EQ-5D) generic quality of life 
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